

Reference Ranges of Glycemic Variability in Infants After Surgery – a Prospective Cohort Study

Supplementary Digital File

CONTENT

| | |
|--|----|
| Figure S1 – CGM system placement on one of the study participants abdomen..... | 2 |
| Table S1. Types of surgeries and the presence of comorbidities in the studied group. ... | 3 |
| Table S2. Continuous glucose monitoring metrics for first 5 post-operative days among infants. | 4 |
| Table S3. STROBE Statement—Checklist | 10 |



Figure S1 – CGM system placement on one of the study participants abdomen

Table S1. Types of surgeries and the presence of comorbidities in the studied group.
Values presented as Ns with %

| | |
|---|------------|
| Type of cardiac defect: | |
| Complete atrioventricular canal (CAVC) | 15 [23.1%] |
| Tetralogy of Fallot (ToF) | 10 [15.4%] |
| Hypoplastic left heart syndrome (HLHS) | 6 [9.2%] |
| Ventricular septal defect (VSD) | 5 [7.7%] |
| Atrial septal defect (ASD) | 3 [4.6%] |
| Hypoplastic right heart syndrome (HRHS) | 3 [4.6%] |
| Total anomalous pulmonary venous return (TAPVR) | 3 [4.6%] |
| Transposition of the great arteries (TGA) | 3 [4.6%] |
| Double outlet right ventricle (DORV) | 3 [4.6%] |
| Other and complex syndromes | 14 [21.5%] |
| Concomitant diseases: | |
| None Down | 45 [69.2%] |
| Syndrome DiGeorge+Down | 10 [15.4%] |
| Syndrome Cornelli de Lange | 1 [1.5%] |
| Syndrome | 1 [1.5%] |
| Costello syndrome | 1 [1.5%] |
| Goldenhar syndrome Annular | 1 [1.5%] |
| pancreas Congenital | 1 [1.5%] |
| laryngomalacia Necrotizing | 1 [1.5%] |
| enterocolitis | 1 [1.5%] |
| Solitary kidney | 1 [1.5%] |
| Multiorgan failure | 1 [1.5%] |

Table S2. Continuous glucose monitoring metrics for first 5 post-operative days among infants. N - number of patients within each day with calculated metric, N% - percentage of patients within each day with calculated metric, -95%CI - lower 95% confidence interval, +95%CI higher 95% confidence interval, SD - standard deviation

| CGM metrics | Day 1 (N=65) | | | | | | | |
|--------------------------------------|--------------|------|--------|--------|--------|---------|---------|--------|
| | N | N% | Mean | -95%CI | +95%CI | Minimum | Maximum | SD |
| ADRR | 65 | 100% | 0.0028 | 0.0025 | 0.0032 | 0.0000 | 0.0061 | 0.0015 |
| CV | 65 | 100% | 17.36 | 15.19 | 19.54 | 7.05 | 52.93 | 8.78 |
| Conga6h | 65 | 100% | 23.88 | 20.70 | 27.06 | 5.16 | 68.06 | 12.82 |
| GMI | 65 | 100% | 6.41 | 6.23 | 6.60 | 5.41 | 8.85 | 0.74 |
| GRADE | 65 | 100% | 4.26 | 3.29 | 5.23 | 0.19 | 17.67 | 3.91 |
| GRADE_Hyper | 65 | 100% | 27.14 | 20.00 | 34.28 | 0.00 | 99.65 | 28.83 |
| HBGI | 65 | 100% | 4.25 | 2.85 | 5.65 | 0.01 | 22.77 | 5.64 |
| Hypo episodes <54 [N] | 65 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| Hypo episodes <70 [N] | 65 | 100% | 0.06 | -0.01 | 0.14 | 0.00 | 2.00 | 0.30 |
| Hyper episodes >180 [N] | 65 | 100% | 0.49 | 0.33 | 0.66 | 0.00 | 2.00 | 0.66 |
| Hyper episodes >250 [N] | 65 | 100% | 0.17 | 0.03 | 0.31 | 0.00 | 4.00 | 0.57 |
| Hypo episodes <54 mean time [min.] | 0 | 0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hypo episodes <70 mean time [min.] | 3 | 5% | 161.67 | 16.11 | 307.22 | 95.00 | 205.00 | 58.59 |
| Hyper episodes >180 mean time [min.] | 26 | 40% | 331.06 | 171.84 | 490.28 | 15.00 | 1255.00 | 394.20 |
| Hyper episodes >250 mean time [min.] | 8 | 12% | 289.38 | 131.09 | 447.66 | 95.00 | 600.00 | 189.33 |
| Hyper episodes >180 max time [min.] | 65 | 100% | 137.46 | 63.82 | 211.11 | 0.00 | 1255.00 | 297.21 |
| Hyper episodes >250 max time [min.] | 65 | 100% | 36.08 | 7.62 | 64.53 | 0.00 | 600.00 | 114.84 |
| Hypo episodes <54 max time [min.] | 65 | 100% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hypo episodes <70 max time [min.] | 65 | 100% | 8.00 | -1.24 | 17.24 | 0.00 | 205.00 | 37.29 |
| J | 65 | 100% | 25.26 | 21.39 | 29.14 | 8.99 | 74.07 | 15.64 |
| LBGI | 65 | 100% | 0.60 | 0.37 | 0.82 | 0.00 | 5.04 | 0.91 |
| MBG [mg/gL] | 65 | 100% | 129.78 | 122.15 | 137.41 | 87.99 | 231.65 | 30.80 |
| Median [mg/dL] | 65 | 100% | 129.13 | 120.88 | 137.38 | 89.00 | 249.00 | 33.28 |
| SD [mg/dL] | 65 | 100% | 23.50 | 19.73 | 27.26 | 6.84 | 71.70 | 15.18 |

| | | | | | | | | |
|--------------------------------------|--------------|------|--------|--------|--------|---------|---------|--------|
| TAR>180 [%] | 65 | 100% | 9.97 | 4.73 | 15.21 | 0.00 | 94.72 | 21.16 |
| TAR>250 [%] | 65 | 100% | 2.91 | 0.71 | 5.11 | 0.00 | 41.67 | 8.88 |
| TBR<54 [%] | 65 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| TBR<70 [%] | 65 | 100% | 0.66 | -0.09 | 1.40 | 0.00 | 15.23 | 3.01 |
| TIR54-180 [%] | 65 | 100% | 90.03 | 84.79 | 95.27 | 5.28 | 100.00 | 21.16 |
| TIR54-250 [%] | 65 | 100% | 97.09 | 94.89 | 99.29 | 58.33 | 100.00 | 8.88 |
| TIR70-180 [%] | 65 | 100% | 89.37 | 84.13 | 94.62 | 5.28 | 100.00 | 21.15 |
| TIR70-250 [%] | 65 | 100% | 96.44 | 94.16 | 98.71 | 58.33 | 100.00 | 9.17 |
| m100 | 65 | 100% | 115.41 | 96.72 | 134.10 | 24.56 | 360.00 | 75.42 |
| CGM metrics | Day 2 (N=62) | | | | | | | |
| | N | N% | Mean | -95%CI | +95%CI | Minimum | Maximum | SD |
| ADRR | 62 | 100% | 0.0027 | 0.0023 | 0.0032 | 0.0000 | 0.0065 | 0.0019 |
| CV | 62 | 100% | 14.14 | 12.67 | 15.62 | 5.58 | 28.41 | 5.81 |
| Conga6h | 62 | 100% | 19.49 | 16.53 | 22.44 | 5.97 | 65.19 | 11.65 |
| GMI | 62 | 100% | 5.82 | 5.72 | 5.93 | 5.09 | 7.15 | 0.42 |
| GRADE | 62 | 100% | 1.87 | 1.44 | 2.31 | 0.19 | 8.16 | 1.71 |
| GRADE_Hyper | 62 | 100% | 8.22 | 4.41 | 12.02 | 0.00 | 64.88 | 14.98 |
| HBGI | 62 | 100% | 1.13 | 0.74 | 1.52 | 0.00 | 7.88 | 1.53 |
| Hypo episodes <54 [N] | 62 | 100% | 0.06 | 0.00 | 0.13 | 0.00 | 1.00 | 0.25 |
| Hypo episodes <70 [N] | 62 | 100% | 0.32 | 0.16 | 0.49 | 0.00 | 3.00 | 0.65 |
| Hyper episodes >180 [N] | 62 | 100% | 0.13 | 0.02 | 0.24 | 0.00 | 2.00 | 0.42 |
| Hyper episodes >250 [N] | 62 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| Hypo episodes <54 mean time [min.] | 4 | 6% | 127.50 | 17.93 | 237.07 | 70.00 | 225.00 | 68.86 |
| Hypo episodes <70 mean time [min.] | 15 | 24% | 112.78 | 38.80 | 186.76 | 15.00 | 545.00 | 133.59 |
| Hyper episodes >180 mean time [min.] | 6 | 10% | 58.33 | -3.28 | 119.94 | 20.00 | 160.00 | 58.71 |
| Hyper episodes >250 mean time [min.] | 0 | 0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hyper episodes >180 max time [min.] | 62 | 100% | 7.42 | -1.11 | 15.95 | 0.00 | 215.00 | 33.61 |
| Hyper episodes >250 max time [min.] | 62 | 100% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hypo episodes <54 max time [min.] | 62 | 100% | 8.23 | -0.68 | 17.13 | 0.00 | 225.00 | 35.08 |
| Hypo episodes <70 max time [min.] | 62 | 100% | 31.61 | 8.17 | 55.05 | 0.00 | 545.00 | 92.30 |
| J | 62 | 100% | 14.90 | 13.41 | 16.39 | 7.72 | 38.68 | 5.85 |

| | | | | | | | | |
|--------------------------------------|--------------|------|--------|--------|--------|---------|---------|--------|
| LBG1 | 62 | 100% | 1.36 | 0.80 | 1.93 | 0.00 | 15.54 | 2.23 |
| MBG [mg/gL] | 62 | 100% | 105.12 | 100.66 | 109.58 | 74.42 | 160.72 | 17.57 |
| Median [mg/dL] | 62 | 100% | 103.89 | 99.32 | 108.45 | 74.00 | 155.00 | 17.97 |
| SD [mg/dL] | 62 | 100% | 14.99 | 13.19 | 16.79 | 5.93 | 37.13 | 7.09 |
| TAR>180 [%] | 62 | 100% | 0.90 | -0.27 | 2.08 | 0.00 | 32.20 | 4.63 |
| TAR>250 [%] | 62 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| TBR<54 [%] | 62 | 100% | 0.62 | -0.03 | 1.27 | 0.00 | 15.63 | 2.57 |
| TBR<70 [%] | 62 | 100% | 2.67 | 0.83 | 4.51 | 0.00 | 37.85 | 7.25 |
| TIR54-180 [%] | 62 | 100% | 98.48 | 97.16 | 99.79 | 67.80 | 100.00 | 5.19 |
| TIR54-250 [%] | 62 | 100% | 99.38 | 98.73 | 100.03 | 84.38 | 100.00 | 2.57 |
| TIR70-180 [%] | 62 | 100% | 96.42 | 94.31 | 98.54 | 62.15 | 100.00 | 8.32 |
| TIR70-250 [%] | 62 | 100% | 97.33 | 95.49 | 99.17 | 62.15 | 100.00 | 7.25 |
| m100 | 62 | 100% | 74.72 | 65.50 | 83.94 | 23.39 | 195.45 | 36.30 |
| | Day 3 (N=46) | | | | | | | |
| CGM metrics | N | N% | Mean | -95%CI | +95%CI | Minimum | Maximum | SD |
| ADRR | 46 | 100% | 0.0032 | 0.0026 | 0.0038 | 0.0000 | 0.0067 | 0.0019 |
| CV | 46 | 100% | 14.70 | 12.57 | 16.82 | 3.25 | 38.93 | 7.14 |
| Conga6h | 46 | 100% | 19.58 | 15.72 | 23.43 | 3.64 | 68.30 | 12.99 |
| GMI | 46 | 100% | 5.73 | 5.57 | 5.89 | 4.99 | 7.46 | 0.53 |
| GRADE | 46 | 100% | 2.08 | 1.53 | 2.62 | 0.26 | 9.83 | 1.84 |
| GRADE_Hyper | 46 | 100% | 7.99 | 2.80 | 13.19 | 0.00 | 84.75 | 17.50 |
| HBGI | 46 | 100% | 1.31 | 0.69 | 1.94 | 0.00 | 9.78 | 2.09 |
| Hypo episodes <54 [N] | 46 | 100% | 0.11 | 0.00 | 0.22 | 0.00 | 2.00 | 0.38 |
| Hypo episodes <70 [N] | 46 | 100% | 1.30 | 0.71 | 1.90 | 0.00 | 7.00 | 2.00 |
| Hyper episodes >180 [N] | 46 | 100% | 0.20 | 0.03 | 0.36 | 0.00 | 3.00 | 0.54 |
| Hyper episodes >250 [N] | 46 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| Hypo episodes <54 mean time [min.] | 4 | 9% | 50.00 | 0.10 | 99.90 | 25.00 | 90.00 | 31.36 |
| Hypo episodes <70 mean time [min.] | 20 | 43% | 90.97 | 51.05 | 130.89 | 20.00 | 400.00 | 85.29 |
| Hyper episodes >180 mean time [min.] | 7 | 15% | 104.76 | 47.06 | 162.46 | 35.00 | 178.33 | 62.39 |
| Hyper episodes >250 mean time [min.] | 0 | 0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hyper episodes >180 max time [min.] | 46 | 100% | 19.02 | 1.64 | 36.40 | 0.00 | 320.00 | 58.52 |

| | | | | | | | | |
|-------------------------------------|--------------|------|--------|--------|--------|---------|---------|--------|
| Hyper episodes >250 max time [min.] | 46 | 100% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hypo episodes <54 max time [min.] | 46 | 100% | 4.46 | -0.46 | 9.37 | 0.00 | 90.00 | 16.54 |
| Hypo episodes <70 max time [min.] | 46 | 100% | 54.89 | 28.46 | 81.33 | 0.00 | 400.00 | 89.02 |
| J | 46 | 100% | 14.26 | 12.12 | 16.41 | 5.82 | 42.17 | 7.22 |
| LBGI | 46 | 100% | 1.97 | 1.45 | 2.49 | 0.00 | 5.66 | 1.76 |
| MBG [mg/gL] | 46 | 100% | 101.12 | 94.54 | 107.71 | 70.06 | 173.63 | 22.17 |
| Median [mg/dL] | 46 | 100% | 99.98 | 93.48 | 106.48 | 70.00 | 164.00 | 21.89 |
| SD [mg/dL] | 46 | 100% | 15.12 | 12.59 | 17.64 | 2.51 | 40.78 | 8.50 |
| TAR>180 [%] | 46 | 100% | 1.68 | -0.12 | 3.47 | 0.00 | 37.94 | 6.04 |
| TAR>250 [%] | 46 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| TBR<54 [%] | 46 | 100% | 0.34 | -0.02 | 0.70 | 0.00 | 6.25 | 1.21 |
| TBR<70 [%] | 46 | 100% | 7.66 | 3.92 | 11.39 | 0.00 | 46.53 | 12.58 |
| TIR54-180 [%] | 46 | 100% | 97.98 | 96.18 | 99.79 | 62.06 | 100.00 | 6.07 |
| TIR54-250 [%] | 46 | 100% | 99.66 | 99.30 | 100.02 | 93.75 | 100.00 | 1.21 |
| TIR70-180 [%] | 46 | 100% | 90.66 | 86.80 | 94.53 | 53.47 | 100.00 | 13.03 |
| TIR70-250 [%] | 46 | 100% | 92.34 | 88.61 | 96.08 | 53.47 | 100.00 | 12.58 |
| m100 | 46 | 100% | 91.76 | 79.18 | 104.33 | 21.08 | 232.68 | 42.35 |
| CGM metrics | Day 4 (N=32) | | | | | | | |
| | N | N% | Mean | -95%CI | +95%CI | Minimum | Maximum | SD |
| ADRR | 32 | 100% | 0.0028 | 0.0020 | 0.0035 | 0.0000 | 0.0066 | 0.0020 |
| CV | 32 | 100% | 14.59 | 12.60 | 16.58 | 5.57 | 26.39 | 5.51 |
| Conga6h | 32 | 100% | 20.27 | 15.98 | 24.56 | 7.82 | 70.20 | 11.90 |
| GMI | 32 | 100% | 5.80 | 5.61 | 6.00 | 4.93 | 7.61 | 0.54 |
| GRADE | 32 | 100% | 2.16 | 1.37 | 2.96 | 0.11 | 10.78 | 2.21 |
| GRADE_Hyper | 32 | 100% | 8.87 | 1.67 | 16.07 | 0.00 | 93.40 | 19.97 |
| HBGI | 32 | 100% | 1.33 | 0.52 | 2.14 | 0.00 | 10.89 | 2.25 |
| Hypo episodes <54 [N] | 32 | 100% | 0.22 | 0.04 | 0.40 | 0.00 | 2.00 | 0.49 |
| Hypo episodes <70 [N] | 32 | 100% | 1.03 | 0.57 | 1.49 | 0.00 | 5.00 | 1.28 |
| Hyper episodes >180 [N] | 32 | 100% | 0.28 | -0.03 | 0.59 | 0.00 | 4.00 | 0.85 |
| Hyper episodes >250 [N] | 32 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| Hypo episodes <54 mean time [min.] | 6 | 19% | 39.17 | 14.02 | 64.31 | 15.00 | 75.00 | 23.96 |

| | | | | | | | | |
|--------------------------------------|--------------|------|--------|--------|--------|---------|---------|--------|
| Hypo episodes <70 mean time [min.] | 18 | 56% | 64.33 | 36.06 | 92.61 | 15.00 | 255.00 | 56.86 |
| Hyper episodes >180 mean time [min.] | 4 | 13% | 128.75 | 0.36 | 257.14 | 20.00 | 192.50 | 80.69 |
| Hyper episodes >250 mean time [min.] | 0 | 0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hyper episodes >180 max time [min.] | 32 | 100% | 24.53 | -4.25 | 53.31 | 0.00 | 350.00 | 79.83 |
| Hyper episodes >250 max time [min.] | 32 | 100% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hypo episodes <54 max time [min.] | 32 | 100% | 7.34 | 0.76 | 13.93 | 0.00 | 75.00 | 18.27 |
| Hypo episodes <70 max time [min.] | 32 | 100% | 57.81 | 12.38 | 103.24 | 0.00 | 690.00 | 126.01 |
| J | 32 | 100% | 15.12 | 12.29 | 17.95 | 5.96 | 41.69 | 7.85 |
| LBG1 | 32 | 100% | 1.82 | 1.20 | 2.44 | 0.00 | 7.20 | 1.72 |
| MBG [mg/gL] | 32 | 100% | 104.24 | 96.04 | 112.44 | 67.76 | 179.93 | 22.74 |
| Median [mg/dL] | 32 | 100% | 104.33 | 96.02 | 112.64 | 68.00 | 182.00 | 23.06 |
| SD [mg/dL] | 32 | 100% | 15.51 | 12.72 | 18.30 | 5.07 | 39.14 | 7.73 |
| TAR>180 [%] | 32 | 100% | 3.03 | -0.80 | 6.86 | 0.00 | 53.47 | 10.63 |
| TAR>250 [%] | 32 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| TBR<54 [%] | 32 | 100% | 0.62 | 0.13 | 1.11 | 0.00 | 5.21 | 1.36 |
| TBR<70 [%] | 32 | 100% | 5.86 | 1.80 | 9.92 | 0.00 | 53.13 | 11.27 |
| TIR54-180 [%] | 32 | 100% | 96.36 | 92.56 | 100.15 | 46.53 | 100.00 | 10.53 |
| TIR54-250 [%] | 32 | 100% | 99.38 | 98.89 | 99.87 | 94.79 | 100.00 | 1.36 |
| TIR70-180 [%] | 32 | 100% | 91.11 | 85.93 | 96.30 | 46.53 | 100.00 | 14.38 |
| TIR70-250 [%] | 32 | 100% | 94.14 | 90.08 | 98.20 | 46.88 | 100.00 | 11.27 |
| m100 | 32 | 100% | 85.88 | 69.00 | 102.76 | 28.41 | 250.96 | 46.81 |
| | Day 5 (N=21) | | | | | | | |
| CGM metrics | N | N% | Mean | -95%CI | +95%CI | Minimum | Maximum | SD |
| ADRR | 21 | 100% | 0.0025 | 0.0016 | 0.0034 | 0.0000 | 0.0061 | 0.0019 |
| CV | 21 | 100% | 14.48 | 12.10 | 16.86 | 6.75 | 25.40 | 5.23 |
| Cong6h | 21 | 100% | 19.06 | 14.63 | 23.49 | 5.15 | 41.31 | 9.73 |
| GMI | 21 | 100% | 5.64 | 5.46 | 5.83 | 4.93 | 6.26 | 0.41 |
| GRADE | 21 | 100% | 1.77 | 1.24 | 2.30 | 0.24 | 4.77 | 1.16 |
| GRADE_Hyper | 21 | 100% | 4.14 | 0.92 | 7.37 | 0.00 | 21.88 | 7.09 |
| HBGI | 21 | 100% | 0.71 | 0.29 | 1.14 | 0.00 | 3.28 | 0.93 |
| Hypo episodes <54 [N] | 21 | 100% | 0.24 | -0.01 | 0.48 | 0.00 | 2.00 | 0.54 |

| | | | | | | | | |
|--------------------------------------|----|------|-------|---------|--------|-------|--------|--------|
| Hypo episodes <70 [N] | 21 | 100% | 1.62 | 0.64 | 2.60 | 0.00 | 7.00 | 2.16 |
| Hyper episodes >180 [N] | 21 | 100% | 0.10 | -0.04 | 0.23 | 0.00 | 1.00 | 0.30 |
| Hyper episodes >250 [N] | 21 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| Hypo episodes <54 mean time [min.] | 4 | 19% | 32.50 | 1.69 | 63.31 | 15.00 | 60.00 | 19.36 |
| Hypo episodes <70 mean time [min.] | 14 | 67% | 60.79 | 28.50 | 93.09 | 15.00 | 227.50 | 55.93 |
| Hyper episodes >180 mean time [min.] | 2 | 10% | 92.50 | -256.92 | 441.92 | 65.00 | 120.00 | 38.89 |
| Hyper episodes >250 mean time [min.] | 0 | 0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hyper episodes >180 max time [min.] | 21 | 100% | 8.81 | -4.46 | 22.08 | 0.00 | 120.00 | 29.15 |
| Hyper episodes >250 max time [min.] | 21 | 100% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hypo episodes <54 max time [min.] | 21 | 100% | 7.62 | -1.84 | 17.08 | 0.00 | 90.00 | 20.77 |
| Hypo episodes <70 max time [min.] | 21 | 100% | 64.52 | 18.79 | 110.26 | 0.00 | 390.00 | 100.47 |
| J | 21 | 100% | 13.01 | 10.70 | 15.32 | 6.27 | 23.38 | 5.08 |
| LBGI | 21 | 100% | 2.10 | 1.17 | 3.03 | 0.02 | 7.62 | 2.04 |
| MBG [mg/gL] | 21 | 100% | 97.57 | 89.72 | 105.41 | 67.90 | 123.23 | 17.24 |
| Median [mg/dL] | 21 | 100% | 96.95 | 89.40 | 104.50 | 69.00 | 124.00 | 16.58 |
| SD [mg/dL] | 21 | 100% | 14.42 | 11.32 | 17.51 | 5.01 | 30.97 | 6.80 |
| TAR>180 [%] | 21 | 100% | 0.63 | -0.29 | 1.56 | 0.00 | 8.33 | 2.03 |
| TAR>250 [%] | 21 | 100% | 0.00 | | | 0.00 | 0.00 | 0.00 |
| TBR<54 [%] | 21 | 100% | 0.90 | -0.48 | 2.27 | 0.00 | 13.79 | 3.02 |
| TBR<70 [%] | 21 | 100% | 9.49 | 2.03 | 16.94 | 0.00 | 52.30 | 16.38 |
| TIR54-180 [%] | 21 | 100% | 98.47 | 96.89 | 100.05 | 86.21 | 100.00 | 3.47 |
| TIR54-250 [%] | 21 | 100% | 99.10 | 97.73 | 100.48 | 86.21 | 100.00 | 3.02 |
| TIR70-180 [%] | 21 | 100% | 89.88 | 82.52 | 97.24 | 47.70 | 100.00 | 16.17 |
| TIR70-250 [%] | 21 | 100% | 90.51 | 83.06 | 97.97 | 47.70 | 100.00 | 16.38 |
| m100 | 21 | 100% | 82.03 | 65.51 | 98.54 | 42.69 | 174.64 | 36.28 |

Table S3. STROBE Statement—Checklist

| | Item No | Recommendation | Pages |
|------------------------------|---------|---|-------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 1 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 1 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 1,2 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 2 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 3 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 3 |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 3 |
| | | (b) For matched studies, give matching criteria and number of exposed and unexposed | - |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 3,4 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 3,4 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 4 |
| Study size | 10 | Explain how the study size was arrived at | - |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 4 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 4 |
| | | (b) Describe any methods used to examine subgroups and interactions | 4 |
| | | (c) Explain how missing data were addressed | 4 |
| | | (d) If applicable, explain how loss to follow-up was addressed | 4 |
| | | (e) Describe any sensitivity analyses | 4 |
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 4 |
| | | (b) Give reasons for non-participation at each stage | 4 |
| | | (c) Consider use of a flow diagram | 4 |

| | | | |
|--------------------------|-----|--|-----|
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 5 |
| | | (b) Indicate number of participants with missing data for each variable of interest | 4 |
| | | (c) Summarise follow-up time (eg, average and total amount) | 4 |
| Outcome data | 15* | Report numbers of outcome events or summary measures over time | 5,6 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 5,6 |
| | | (b) Report category boundaries when continuous variables were categorized | 5,6 |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | - |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | - |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 8,9 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 9 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 8,9 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 9 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 10 |

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.